Ar­genx scraps pro­gram in skin au­toim­mune dis­ease af­ter Vyv­gart Hytru­lo flunks an­oth­er PhI­II tri­al

Ar­genx’s au­toim­mune dis­ease drug Vyv­gart Hytru­lo flunked its sec­ond late-stage tri­al in as many months, and the com­pa­ny is aban­don­ing the in­di­ca­tion al­to­geth­er.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.